Emcure Pharmaceuticals Ltd. has reduced the prices of its obesity drug Poviztra® (semaglutide injection) by an average of 47% across all dosage strengths, with the steepest cut of 55% seen in the starting dose.
The 0.25 mg dose is now priced at Rs. 3,999 per month, while the highest dose (2.4 mg) has been reduced from Rs. 15,000 to Rs. 8,999.
Effective April 3, 2026, the revised pricing aims to expand access to semaglutide, a globally studied molecule with over 49 million patient-years of exposure and nearly 50 clinical trials supporting its use.
The therapy is administered through a once-weekly injection using a pen device designed for convenience and accuracy.
Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity.3 Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”
